Our Product Development Initiatives
Our product development initiatives will address unmet medical needs in health care.
PRODUCT
DELIVERY
TECHNOLOGY
INDICATION
GLOBAL
MARKET SIZE (1)
ESTIMATED
PRODUCT
LAUNCH
PGS-N001
Solmic Solubilisate / Oral
Cancer supportive care (CINV) (chemo-induced nausea and vomiting)
>$1B
2018
PGS-N002
Solmic Solubilisate / Oral
Restless leg syndrome
>$2B
2018
PGS-N003
Solmic Solubilisate / Oral
Pain and inflammation (for opioid withdrawal)
>$15B
2018
PGS-N004
Solmic Solubilisate / Oral
Cancer supportive care (mucositis relief)
>$12B
2018
PGS-N005
BiPhasix / Topical
Female sexual dysfunction (HSDD) (hypoactive sexual desire disorder)
>$6B
2019
PGS-N006
BiPhasix / Topical
Pain and inflammation (joints/opioid withdrawal)
>$20B
2018
PGS-N007
BiPhasix / Topical
Dermatology (skin irritation/redness/ itching)
>$13B
2018
PGS-N008
BiPhasix / Topical
Eye disease (glaucoma, intra-ocular pressure)
>$3B
2019
PGS-N009
Thrudermic / Topical
Pain and inflammation (opioid withdrawal)
>$15B
2018
PGS-N010
Solmic Solubilisate / Oral
Migraine (nausea, vomiting, dizziness, sensitivity to light, sounds and smells)
>$10B
2019
News 
Market Data 
Discover 
